2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 619

Effect of ERAP1 Knockdown on Conformation of HLA-B27 and Other HLA Class I Molecules in Human Monocytic Cells
Abstract Number: 337

Effect of Etanercept on Endothelial Dysfunction in Rat Adjuvant-Induced Arthritis
Abstract Number: 64

Effect of Family Support on Short-and Intermediate Term Pain and Function Outcomes after Knee or Hip Replacement
Abstract Number: 2522

Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations
Abstract Number: 1603

Effect of Methotrexate on the Immunogenicity of TNF Inhibitors in Spondyloarthritis Patients
Abstract Number: 2783

Effect of Synovitis, Effusion and Bone Marrow Lesions on Development of Sensitization in Knee OA: The Multicenter Osteoarthritis Study
Abstract Number: 2471

Effect of Teriparatide in Patients with Osteoporosis and Rheumatoid Arthritis
Abstract Number: 2253

Effect of Teriparatide in Patients with Osteoporosis with Prior Vertebral Fracture
Abstract Number: 182

Effect of Urate-Lowering Therapy on Radiographic Changes in Gout Patients
Abstract Number: 2552

Effectiveness and Safety of Low-Dose Cyclosporine a in Patients with Primary Sjögren’s Syndrome (pSS) with Articular Involvement – Results of a Pilot Study
Abstract Number: 2467

Effectiveness and Safety of Tocilizumab in Biologics NaÃ¯ve RA Patients – Interim Analysis of PMS for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-NaÃ¯ve RA Patients Study
Abstract Number: 2128

Effectiveness of ¹⁸f-Fluoro-Dexoxyglucose Positron Emission Tomography for the Diagnosis of Polymyalgia-like Illness
Abstract Number: 2780

Effectiveness of a Sequential Treatment with Intravenous Prostaglandins Followed By Bosentan in Patients with Buerger Disease and Severe Ischemic Lesions: A Case Series
Abstract Number: 2104

Effectiveness of a Workplace Integrated Care Intervention on Work Productivity in Workers with Rheumatoid Arthritis
Abstract Number: 2366

Effectiveness, Tolerability, and Safety of Subcutaneous Methotrexate in Early Rheumatoid Arthritis: Clinical Data from the St. Gallen Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].